"Normal Coronary Artery" With Slow Flow Improved by Adenosine Injection, Dipyridamole Treatment and Clinical Follow-up

Coronary Angiography Clinical Trial

Official title:

"Normal Coronary Artery" With Slow Flow Improved by Adenosine Injection, Dipyridamole Treatment and Clinical Follow-up

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT00960817
• Other study ID #: HYMC 02/2009
• Status: Not yet recruiting
• Phase: Phase 0
• First received: August 17, 2009
• Last updated: August 17, 2009

Study information

• Verified date: August 2009
• Source: Hillel Yaffe Medical Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: Israel: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

The investigators will investigate patients undergoing coronary angiography with normal coronary but slow blood flow that was normalized after adenosine injection into the coronary artery. The investigators believe that they have small vessel coronary disease which is the initial presentation of coronary disease prior to anatomical narrowing. To alleviate this phenomenon the investigators intend to examine the long-term clinical response of these patients to treatment with dipyridamole, a well-known medication with almost no side-effects that increases the level of adenosine in the tissue.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 0
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Patients undergoing coronary angiography and who have normal coronary artery with slow blood flow that normalized with adenosine injection into the coronary artery

Exclusion Criteria:

• Significant coronary disease

• Unstable patients

• Patients with known sensitivity to dipyridamole

Study Design

N/A

Related Conditions & MeSH terms

• Coronary Angiography

Intervention

Drug:
• Statin, aspirin

• Dipyridamole

Locations

Country	Name	City	State
Israel	Hillel Yaffe Medical Center	Hadera

Sponsors (1)

Lead Sponsor	Collaborator
Hillel Yaffe Medical Center

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Alleviation of chest pain		Two years	No